But of course I looked at the chart and saw what happened. I just drew up the chart from that specific period in June/July 2013. The PPS had climbed up around $3 and then the results came out and the bottom fell out....all the way under $0.25....less than a Canadian quarter.
I started my DD on RVX after this black swan event....and what stood out to me was what happened almost immediately following this precipitous drop. Two days after the fall under 25 cents the PPS shot back up to about $1.00, more than a four fold increase. It didn't stay there of course...but if it had been a so called "dead cat" bounce it would have gone back under a quarter and then kept falling.
It didn't take RVX long to establish a base in and around 75 cents or so....and I formed the opinion that RVX was being accumulated by smart money types. The way I see things the trial failure caused the sheep to jump ship, but there were enough buyers willing to take their shares from them that the PPS found decent support in a very short period of time.
Now of course we're at a similar such point....so I can understand the apprehension some might be having, I have it too. Even though I didn't experience that bad news event, I know what they feel like....a punch to the gut. And history can repeat.....
Could something similiar happen? Could the company report a miss on the primary, but still achieve success down the road from the secondary end points?
If they report missing the primary I have little doubt that there would be deep pocketed players ready to hammer the PPS by borrowing and dumping a ton of shares...that's my opinion.
I still haven't worked out all my thoughts on this....I'm hoping in the 2 months or so we have left until Top-Line results come out....I'm hoping we're up around $10....that'll make decisions easier and if it happens I'll likely hedge.
If you want to taste the fruit, you have to go out on a limb. But if you wait for the herd to move out on the limb....the branch tends to snap.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM